In this podcast episode, we take on the challenge of treatment-resistant depression and its therapeutic options. Dr. Philip Cowen (University of Oxford) provided insights for this clinical conundrum with a simple algorithm.Read More
In this episode, we venture into the psychopharmacology of agitation, with a special focus on psychotic agitation. Dr. Michael Jibson (University of Michigan) and Dr. David Osser (Harvard Medical School) shared clinical pearls to treat this challenging situation.Read More
This presentation reviews the effects of serotonin receptors (5-HTR) on domains such as impulsivity/aggression, anxiety/stress, and cognition. It also discusses findings from neuroimaging studies involving 5-HT1A and 5-HT2A receptors.Read More
This presentation discusses how to address partial response to pharmacotherapy in the treatment of GAD. When to switch and when to augment. Dr. Osser gives three options for augmentation.Read More
When is the right time to discontinue an antipsychotic in the treatment of schizophrenia? We reviewed the evidence as well as consulting Dr. Ira Glick to help us answer this question.Read More
This presentation discusses the pharmacotherapy of generalized anxiety disorder (GAD). More specifically, it summarizes how to treat comorbid conditions (bipolar disorder, PTSD, substance use, insomnia) and considerations in special populations (elderly and women of childbearing potential).Read More
What is the role of antidepressants in the treatment of irritable bowel syndrome? How is drug absorption affected after gastric bypass surgery? This presentation gives practical answers to these questions.Read More
Dr. Jeffrey Mattes, psychiatrist in Princeton, New Jersey speaks about drug interaction warnings that appear during electronic prescribing and how these warnings may be influenced by drug company promotion.
This interview is part of a series covering the 2018 ASCP Annual Meeting.